Schonfeld Strategic Advisors
GTBP icon

Schonfeld Strategic Advisors’s GT Biopharma GTBP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17
Closed -$23K – 2767
2022
Q3 		$23K Sell
17
-4
-19% -$7.65K ﹤0.01% 2707
2022
Q2 		$46K Buy
21
+1
+5% +$1.9K ﹤0.01% 2232
2022
Q1 		$43K Buy
+20
New +$44.1K ﹤0.01% 2355

Other funds holding GTBP

Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baskin Financial Services
Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Schonfeld Strategic Advisors's GTBP Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of GT Biopharma (GTBP) in Q4 2022, closing a stake of 17 shares — an estimated $23K sold.

Schonfeld Strategic Advisors first reported a position in GTBP in Q1 2022 and held it in 3 quarters. The position peaked at $46K in Q2 2022. 26 funds tracked by Wall St. Rank hold GTBP as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining GT Biopharma position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 17 GT Biopharma shares in Q4 2022, an estimated $23K.
  • Schonfeld Strategic Advisors first reported a position in GT Biopharma in Q1 2022 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's GT Biopharma position peaked at $46K in Q2 2022.
  • 26 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.